Iranian Society of Gynecology Oncology


1 Department of Hematology and Oncology, Hazrat Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, IR Iran

2 Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, IR Iran

3 Hospital Pharmacy Management, Iran University Medical Sciences, Tehran, IR Iran


Background: Anemia is prevalent in 32% to 60% of patients with cancer due to an underlying disease, nutritional deficiencies and complications of medication used in chemotherapy. National Comprehensive Cancer Network (NCCN) recommends the use of oral or intravenous iron supplementation in patients with iron deficiency anemia.


  1. World Health Organization . Iron deficiency anemia: assessment. Prevention And Control.; 2001.
  2. Arora NP, Ghali JK. Iron deficiency anemia in heart failure. Heart Fail Rev. 2013;18(4):485-501. doi: 10.1007/s10741-012-9342-y. [DOI:10.1007/s10741-012-9342-y]
  3. Goddard AF, James MW, McIntyre AS, Scott BB, British Society of G. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10):1309-16. doi: 10.1136/gut.2010.228874. [DOI:10.1136/gut.2010.228874]
  4. Breymann C, Bian XM, Blanco-Capito LR, Chong C, Mahmud G, Rehman R. Expert recommendations for the diagnosis and treatment of iron-deficiency anemia during pregnancy and the postpartum period in the Asia-Pacific region. J Perinat Med. 2011;39(2):113-21. [DOI:10.1515/jpm.2010.132]
  5. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis (CME). Transfusion. 2012;52(7):1584-92. [DOI:10.1111/j.1537-2995.2011.03495.x]
  6. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum. 1997;40(1):15-24. [DOI:10.1007/BF02055676]
  7. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93(4):1721-41. [DOI:10.1152/physrev.00008.2013]
  8. Hedenus M, Karlsson T, Ludwig H, Rzychon B, Felder M, Roubert B, et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol. 2014;31(12):302. [DOI:10.1007/s12032-014-0302-3]
  9. Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject): structure/reactivity relationships of iron preparation. Port J Nephrol Hypert. 2009;23(1):11-6.
  10. Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung. 2010;60(6a):345-53. [DOI:10.1055/s-0031-1296299]
  11. Geisser P, Rumyantsev V. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron deficiency anaemia secondary to a gastrointestinal disorder. Arzneimittelforschung. 2010;60(6a):373-85. [DOI:10.1055/s-0031-1296302]
  12. Geisser P, Banke-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung. 2010;60(6a):362-72. [DOI:10.1055/s-0031-1296301]
  13. Bisbe E, Molto L, Arroyo R, Muniesa JM, Tejero M. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. Br J Anaesth. 2014;113(3):402-9. [DOI:10.1093/bja/aeu092]
  14. National Comprehensive Cancer Network . clinical practice guidelines in oncology (NCCN guidelines). Cancer and chemotheraphy induced anemia 2015. [cited 6 Nov]. Available from:
  15. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48. [DOI:10.1056/NEJMoa0908355]
  16. Borstlap WA, Buskens CJ, Tytgat KM, Tuynman JB, Consten EC, Tolboom RC, et al. Multicentre randomized controlled trial comparing ferric(III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients. BMC Surg. 2015;15:78. [DOI:10.1186/s12893-015-0090-5]
  17. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475-82. doi: 10.1093/annonc/mds338. [DOI:10.1093/annonc/mds338]
  18. Toledano A, Luporsi E, Morere JF, Scotte F, Huot-Marchand P, Zakin L, et al. Observational study of ferric carboxymaltose (FCM) in france (oncofer study; interim analysis). Value Health. 2013;16(3):A112. [DOI:10.1016/j.jval.2013.03.537]
  19. Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol. 2013;131(3):679-82. [DOI:10.1016/j.ygyno.2013.09.028]